<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00250679</url>
  </required_header>
  <id_info>
    <org_study_id>091-061</org_study_id>
    <nct_id>NCT00250679</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 μg and 25 μg Arformoterol Tartrate Inhalation Solution BID in Subjects With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a
      period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, double-dummy, multicenter, randomized, active-controlled, parallel
      group, outpatient, safety study to evaluate the long term safety of arformoterol in the
      treatment of subjects with COPD. Study participation will be over approximately 6 months.
      This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired
      by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to
      Sunovion Pharmaceuticals Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations</measure>
    <time_frame>Six months</time_frame>
    <description>Percent of participants with the adverse event specified.
SOC = system organ class.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New 24-Hour Holter Monitoring Alerts</measure>
    <time_frame>Visit 6 (week 27)</time_frame>
    <description>New holter monitoring alerts are defined as those alerts that occurred post-randomization and were not present at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Glucose Evaluations</measure>
    <time_frame>visit 6 (week 27)</time_frame>
    <description>Patients with glucose values that met low (&lt;=40 mg/dL) or high (&gt;=175 mg/dL) criteria were considered potentially clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Potassium Evaluations</measure>
    <time_frame>visit 6 (week 27)</time_frame>
    <description>Patients with potassium values that met low (&lt;=3 mEq/L) or high (&gt;=6 mEq/L) criteria were considered potentially clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New 12-Lead Electrocardiogram (ECG) Alerts</measure>
    <time_frame>visit 6 (week 27)</time_frame>
    <description>New Electrocardiogram (ECG) alerts are defined as those alerts that occurred post-treatment and were not present at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity Changes From Baseline</measure>
    <time_frame>weeks 0,3,13,26</time_frame>
    <description>Mean Change in Inspiratory Capacity values from baseline (baseline assessment obtained at Visit 2, pre-dose). Spirometry measurements collected within 6 hours following in-clinic rescue/supplemental medications use were excluded from analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-Hour Peak Changes From Baseline in Forced Expiratory Volume (FEV1)</measure>
    <time_frame>weeks 0,3,13,26</time_frame>
    <description>The 6 hour peak change from baseline is the maximum of the post-dose change values through 6 hours at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Heart Rate</measure>
    <time_frame>visit 6 (week 27)</time_frame>
    <description>Number of subjects with a heart rate that was lower/higher than a set limit and increased/decreased from set baseline limit in beats per minute (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Days Used Per Week</measure>
    <time_frame>Screening (day-14 to 0) and Treatment (week 0 - 26)</time_frame>
    <description>Supplemental medication usage is recorded throughout the study. MDI stands for metered dose inhaler.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day</measure>
    <time_frame>Screening (day-14 to 0) and Treatment (week 0 - 26)</time_frame>
    <description>Supplemental medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Days Used Per Week</measure>
    <time_frame>Screening (day-14 to 0) and Treatment (week 0 - 26)</time_frame>
    <description>Rescue medication usage during the study. MDI stands for metered dose inhaler.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day</measure>
    <time_frame>Screening (day-14 to 0) and Treatment (week 0 - 26)</time_frame>
    <description>Rescue medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-Normalized Area Under the Curve (nAUC) From 0 to 6 Hrs for Forced Expiratory Volume in One Second (FEV1) Changes From Baseline</measure>
    <time_frame>weeks 0,3,13,26</time_frame>
    <description>Area under the change from baseline curve from 0 to 6 hours. Time-normalized AUC (0-6 hrs) was derived using the linear trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transitional (Relative Change in) Dyspnea Index</measure>
    <time_frame>weeks 13, 26</time_frame>
    <description>The transitional focal score (-9 to 9) is the sum of relative change from baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores (each -3 to 3 scale). A Transitional Dyspnea Index score of -9 represents a maximum degradation of all three tests; a score of 9 represents a maximum improvement of all three tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Improved Transitional Dyspnea Index</measure>
    <time_frame>weeks 13, 26</time_frame>
    <description>The number of participants with a transitional focal score (range -9 to 9) of &gt;=1 improvement. Transitional focal score compares current health against baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Changes From Baseline for 24 Hour Post Dose Timepoint (Trough)</measure>
    <time_frame>weeks 0,3,13,26</time_frame>
    <description>The 24 hour trough is the FEV1 value obtained 24 hours post first dose. This value is compared to the baseline FEV1 value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Evaluations Change From Baseline</measure>
    <time_frame>weeks 13, 26</time_frame>
    <description>The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1=much better and 7=much worse. Ratings were assessed relative to the subject's initial entry into the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Evaluations Change From Baseline</measure>
    <time_frame>weeks 13, 26</time_frame>
    <description>The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse. Ratings were assessed relative to the subject's initial entry into the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BODE Index</measure>
    <time_frame>Baseline (visit 2), weeks 13, 26</time_frame>
    <description>The BODE index (0=relative health and 10=severe chronic obstructive pulmonary disease) is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the 6-minute walk test. Scores were derived using pre-dose assessments from each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-Minute Walk: Change From Baseline in the Distance Walked in 6 Minutes</measure>
    <time_frame>Post-Dose weeks 0, 13, 26</time_frame>
    <description>Mean change from baseline in distance walked (meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in St. George's Respiratory Questionnaire</measure>
    <time_frame>weeks 13, 26</time_frame>
    <description>Scores are expressed as a mean change from baseline of overall impairment (total score). The questionnaire has a scale of 100 which represents worst possible health status to 0 which indicates best possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a &gt;=4 Unit Improvement on the St. George's Respiratory Questionnaire</measure>
    <time_frame>Visit 4 (week 13) , Visit 5 (week 26)</time_frame>
    <description>Scores are expressed as the number of participants with &gt;= 4 unit improvement in overall impairment (total score), where 100 represents worst possible health status and 0 indicates best possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Medical Research Council Dyspnea Questionaire</measure>
    <time_frame>Baseline (visit 2), weeks 13, 26</time_frame>
    <description>Scores range from 0 to 4, with a score of 4 indicating that a subject is too breathless to leave the house or becomes breathless when dressing or undressing. The highest numbered question to which the subject answered 'Yes' is the Dyspnea Scale Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent (%) of Participants With an Improved Transitional Dyspnea Index</measure>
    <time_frame>visits 4 (week 13), visit 5 (week 26)</time_frame>
    <description>The percentage of participants with a transitional focal score (range -9 to 9) of &gt;=1 improvement. Transitional focal score is the sum of the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent (%) of Participants With a &gt;=4 Unit Improvement in the St. George's Respiratory Questionaire</measure>
    <time_frame>visit 4 (week 13), visit 5 (week 26)</time_frame>
    <description>Percent of participants with a &gt;=4 unit improvement in the overall impairment (total score) of the St. George's Respiratory Questionaire. This questionaire uses a 100 - 0 scale, where 100 represents the worst possible health status and 0 indicates the best possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for the 6-Minute Walk Test: Distance Walked in Meters</measure>
    <time_frame>Baseline (Visit 2), week 13, week 26</time_frame>
    <description>This test measures the participants' level of fitness. It is a measure of the distance the participant can walk in 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for Investigator Global Evaluations</measure>
    <time_frame>Baseline (Visit 2), Weeks 13, 26</time_frame>
    <description>The investigator global evaluation is reported by the study investigator. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for St. George's Respiratory Questionnaire</measure>
    <time_frame>Baseline (Visit 2), weeks 13, 26</time_frame>
    <description>A questionnaire to assess respiratory health. Scores are expressed as a percentage of overall impairment (total score), where 100 represents the worst possible health status and 0 indicates best possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for Subject Global Evaluations</measure>
    <time_frame>Baseline (Visit 2), weeks 13, 26</time_frame>
    <description>The subject global evaluation is reported by study subjects/participants. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for Inspiratory Capacity</measure>
    <time_frame>Baseline (Visit 2), Weeks 3, 13, 26</time_frame>
    <description>Inspiratory capacity is the maximum volume that can be inhaled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Values for Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Baseline (Visit 2), weeks 3, 13, 26</time_frame>
    <description>Forced Expiratory Volume in one second</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">443</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Bronchitis</condition>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>Formoterol 12 ųg 2x/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arformoterol 15 ųg 2x/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arformoterol 25 ųg 2x/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arformoterol tartrate inhalation solution</intervention_name>
    <description>Arformoterol 15 ųg BID by nebulization</description>
    <arm_group_label>Arformoterol 15 ųg 2x/day</arm_group_label>
    <other_name>Brovana®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arformoterol 25 ųg BID</intervention_name>
    <description>Arformoterol 25 ųg BID by nebulization</description>
    <arm_group_label>Arformoterol 25 ųg 2x/day</arm_group_label>
    <other_name>Brovana</other_name>
    <other_name>R,R formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol 12 ųg BID</intervention_name>
    <description>Formoterol fumarate 12 ųg BID via aerolizer/DPI</description>
    <arm_group_label>Formoterol 12 ųg 2x/day</arm_group_label>
    <other_name>Foradil</other_name>
    <other_name>R,S-formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo nebule or placebo aerolizer</description>
    <arm_group_label>Formoterol 12 ųg 2x/day</arm_group_label>
    <arm_group_label>Arformoterol 15 ųg 2x/day</arm_group_label>
    <arm_group_label>Arformoterol 25 ųg 2x/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male and female subjects must be at least 35 years old at the time of consent

          -  Subjects must have a pre-established, documented primary clinical diagnosis of
             non-asthmatic COPD or are referred for diagnosis of non-asthmatic COPD

          -  Subjects must have a &gt;=15 pack-year smoking history and a baseline breathlessness
             severity grade of &gt;=2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score)
             at Visits 1 and 2

          -  Female subjects &lt;=65 years of age must have a negative serum pregnancy test, females
             of childbearing potential must be using an acceptable method of birth control

          -  Subjects must be in general good health.

        Key Exclusion criteria:

          -  Subjects with a history of asthma, with the exception of asthma diagnosed in childhood

          -  Subjects with a blood eosinophil count &gt;5% of total white blood cell count

          -  Subjects have had a febrile illness within 72 hours (3 days) before Screening Visit 1

          -  Subjects with a chest x-ray that suggests a diagnosis other than COPD (e.g.,
             diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other
             active/ongoing pulmonary conditions)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sepracor Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Slidell</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chester</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Swarthmore</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hanania NA, Donohue JF, Nelson H, Sciarappa K, Goodwin E, Baumgartner RA, Hanrahan JP. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb;7(1):17-31. doi: 10.3109/15412550903499498.</citation>
    <PMID>20214460</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2005</study_first_submitted>
  <study_first_submitted_qc>November 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2005</study_first_posted>
  <results_first_submitted>October 3, 2008</results_first_submitted>
  <results_first_submitted_qc>February 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 19, 2009</results_first_posted>
  <last_update_submitted>May 29, 2012</last_update_submitted>
  <last_update_submitted_qc>May 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>chronic bronchitis</keyword>
  <keyword>emphysema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two patients were each issued two randomization numbers; both subjects are included only once in the intent-to-treat (ITT) population. One additional subject was randomized in error and did not receive study drug. This subject is excluded from the ITT population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Formoterol 12 Mcg 2x/Day</title>
        </group>
        <group group_id="P2">
          <title>Arformoterol 15 Mcg 2x/Day</title>
        </group>
        <group group_id="P3">
          <title>Arformoterol 25 Mcg 2x/Day</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Does Not Meet Entry Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical Holter issues</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>various single events: hip surgery,diary</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Formoterol 12 Mcg 2x/Day</title>
        </group>
        <group group_id="B2">
          <title>Arformoterol 15 Mcg 2x/Day</title>
        </group>
        <group group_id="B3">
          <title>Arformoterol 25 Mcg 2x/Day</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="147"/>
            <count group_id="B4" value="443"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="7.8"/>
                    <measurement group_id="B2" value="65.4" spread="9.0"/>
                    <measurement group_id="B3" value="63.8" spread="8.6"/>
                    <measurement group_id="B4" value="64.4" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in 30 days prior to screening</title>
          <description>Number of patients with a specified number of COPD exacerbations in the 30 days prior to screening. COPD stands for 'chronic obstructive pulmonary disease' and is a progressive disease that makes it hard to breath. Exacerbations refers to a worsening of the condition.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title># Packs Currently Smoked Per Day</title>
          <description>Number of participants with a specified range of packs of cigarettes smoked per day.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 packs per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;0 - &lt;=1 packs per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1 - &lt;=2 packs per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 - &lt;=4 packs per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;4 packs per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Pack-Years Smoked</title>
          <description>Number of participants with a specified number range of pack years smoked. Number of pack years smoked is defined as the number of cigarette packs smoked per day times the number of years smoked.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 15 pack years smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 15 - &lt; 25 pack years smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 25 - &lt; 30 pack years smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 30 pack years smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oral or Inhaled Steroid Use</title>
          <description>Number of participants taking oral or inhaled corticosteriod at baseline. These were allowed at study entry and for the duration of the study as long as the regimen was stable for at least 14 days prior to entry and throughout the study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Dyspnea Index</title>
          <description>Baseline Dyspnea Index (range 0-12) is defined to be the sum of the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores (each on a 0-4 scale) obtained at visit 2 (baseline). On each scale, a high measurement represents the most impairment to health.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.34" spread="1.72"/>
                    <measurement group_id="B2" value="5.34" spread="2.18"/>
                    <measurement group_id="B3" value="5.10" spread="2.38"/>
                    <measurement group_id="B4" value="5.26" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Volume (FEV1)</title>
          <description>FEV1 stands for 'forced expiratory volume 1 second'. It is the amount of air that you can forcibly blow out in one second, measured in liters</description>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.210" spread="0.420"/>
                    <measurement group_id="B2" value="1.222" spread="0.465"/>
                    <measurement group_id="B3" value="1.204" spread="0.422"/>
                    <measurement group_id="B4" value="1.212" spread="0.435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent Predicted Forced Expiratory Volume (FEV1)</title>
          <description>FEV1 stands for 'forced expiratory volume 1 second'. It is the amount of air that you can forcibly blow out in one second, measured in liters. FEV1 can be predicted using patients' height and age. This value is the percent of the predicted FEV1.</description>
          <units>percent predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.19" spread="11.52"/>
                    <measurement group_id="B2" value="40.87" spread="13.59"/>
                    <measurement group_id="B3" value="40.22" spread="12.22"/>
                    <measurement group_id="B4" value="40.76" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations</title>
        <description>Percent of participants with the adverse event specified.
SOC = system organ class.</description>
        <time_frame>Six months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations</title>
          <description>Percent of participants with the adverse event specified.
SOC = system organ class.</description>
          <population>ITT Population</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="67.8"/>
                    <measurement group_id="O3" value="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="13.4"/>
                    <measurement group_id="O3" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Potentially Related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7"/>
                    <measurement group_id="O2" value="32.9"/>
                    <measurement group_id="O3" value="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Beta-Mediated AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE w SOC of Cardiac Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="6.0"/>
                    <measurement group_id="O3" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="13.4"/>
                    <measurement group_id="O3" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="10.1"/>
                    <measurement group_id="O3" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any COPD Exacerbation (Protocol Definition)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                    <measurement group_id="O2" value="32.2"/>
                    <measurement group_id="O3" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any COPD Exacerbation (Expanded Definition)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="35.6"/>
                    <measurement group_id="O3" value="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ischaemic AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Arrhythmnic AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE w SOC Respiratory, Thoracic, &amp; Mediastinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="34.2"/>
                    <measurement group_id="O3" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New 24-Hour Holter Monitoring Alerts</title>
        <description>New holter monitoring alerts are defined as those alerts that occurred post-randomization and were not present at baseline.</description>
        <time_frame>Visit 6 (week 27)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New 24-Hour Holter Monitoring Alerts</title>
          <description>New holter monitoring alerts are defined as those alerts that occurred post-randomization and were not present at baseline.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potentially Clinically Significant Glucose Evaluations</title>
        <description>Patients with glucose values that met low (&lt;=40 mg/dL) or high (&gt;=175 mg/dL) criteria were considered potentially clinically significant.</description>
        <time_frame>visit 6 (week 27)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Glucose Evaluations</title>
          <description>Patients with glucose values that met low (&lt;=40 mg/dL) or high (&gt;=175 mg/dL) criteria were considered potentially clinically significant.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=40 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=175 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potentially Clinically Significant Potassium Evaluations</title>
        <description>Patients with potassium values that met low (&lt;=3 mEq/L) or high (&gt;=6 mEq/L) criteria were considered potentially clinically significant.</description>
        <time_frame>visit 6 (week 27)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Potassium Evaluations</title>
          <description>Patients with potassium values that met low (&lt;=3 mEq/L) or high (&gt;=6 mEq/L) criteria were considered potentially clinically significant.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;= 3mEq/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 6mEq/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New 12-Lead Electrocardiogram (ECG) Alerts</title>
        <description>New Electrocardiogram (ECG) alerts are defined as those alerts that occurred post-treatment and were not present at baseline.</description>
        <time_frame>visit 6 (week 27)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New 12-Lead Electrocardiogram (ECG) Alerts</title>
          <description>New Electrocardiogram (ECG) alerts are defined as those alerts that occurred post-treatment and were not present at baseline.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inspiratory Capacity Changes From Baseline</title>
        <description>Mean Change in Inspiratory Capacity values from baseline (baseline assessment obtained at Visit 2, pre-dose). Spirometry measurements collected within 6 hours following in-clinic rescue/supplemental medications use were excluded from analysis.</description>
        <time_frame>weeks 0,3,13,26</time_frame>
        <population>ITT Population This outcome was added as an amendment after the study was initiated; therefore approximately half of the ITT population had these assessments at baseline. An available cases analysis was performed with no imputation for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity Changes From Baseline</title>
          <description>Mean Change in Inspiratory Capacity values from baseline (baseline assessment obtained at Visit 2, pre-dose). Spirometry measurements collected within 6 hours following in-clinic rescue/supplemental medications use were excluded from analysis.</description>
          <population>ITT Population This outcome was added as an amendment after the study was initiated; therefore approximately half of the ITT population had these assessments at baseline. An available cases analysis was performed with no imputation for missing data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (wk 0): 2 hours Post-dose n=79,85,80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.240" spread="0.363" lower_limit="0.158" upper_limit="0.321"/>
                    <measurement group_id="O2" value="0.297" spread="0.300" lower_limit="0.232" upper_limit="0.361"/>
                    <measurement group_id="O3" value="0.330" spread="0.354" lower_limit="0.251" upper_limit="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (wk 3): Pre-Dose n=74,77,69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.058" spread="0.380" lower_limit="-0.030" upper_limit="0.146"/>
                    <measurement group_id="O2" value="0.032" spread="0.409" lower_limit="-0.060" upper_limit="0.125"/>
                    <measurement group_id="O3" value="0.124" spread="0.370" lower_limit="0.035" upper_limit="0.212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (wk 3): 2 hours Post-dose n=75,75,69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.206" spread="0.410" lower_limit="0.111" upper_limit="0.300"/>
                    <measurement group_id="O2" value="0.241" spread="0.401" lower_limit="0.149" upper_limit="0.333"/>
                    <measurement group_id="O3" value="0.331" spread="0.448" lower_limit="0.223" upper_limit="0.438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (wk 13): Pre-Dose n=62,63,58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.114" spread="0.368" lower_limit="0.020" upper_limit="0.207"/>
                    <measurement group_id="O2" value="0.005" spread="0.441" lower_limit="-0.106" upper_limit="0.116"/>
                    <measurement group_id="O3" value="0.124" spread="0.447" lower_limit="0.006" upper_limit="0.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (wk 13): 2 hours Post-Dose n=60,63,58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.290" spread="0.445" lower_limit="0.174" upper_limit="0.405"/>
                    <measurement group_id="O2" value="0.233" spread="0.364" lower_limit="0.141" upper_limit="0.325"/>
                    <measurement group_id="O3" value="0.284" spread="0.423" lower_limit="0.173" upper_limit="0.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (wk 26): Pre-Dose n=58,58,53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.354" lower_limit="-0.054" upper_limit="0.132"/>
                    <measurement group_id="O2" value="0.057" spread="0.326" lower_limit="-0.029" upper_limit="0.142"/>
                    <measurement group_id="O3" value="0.154" spread="0.371" lower_limit="0.051" upper_limit="0.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (wk 26): 2 hours Post-Dose n=58,58,53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.234" spread="0.451" lower_limit="0.116" upper_limit="0.353"/>
                    <measurement group_id="O2" value="0.202" spread="0.402" lower_limit="0.097" upper_limit="0.308"/>
                    <measurement group_id="O3" value="0.368" spread="0.443" lower_limit="0.245" upper_limit="0.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6-Hour Peak Changes From Baseline in Forced Expiratory Volume (FEV1)</title>
        <description>The 6 hour peak change from baseline is the maximum of the post-dose change values through 6 hours at each visit.</description>
        <time_frame>weeks 0,3,13,26</time_frame>
        <population>ITT population. An available cases analysis was performed with no imputation for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>6-Hour Peak Changes From Baseline in Forced Expiratory Volume (FEV1)</title>
          <description>The 6 hour peak change from baseline is the maximum of the post-dose change values through 6 hours at each visit.</description>
          <population>ITT population. An available cases analysis was performed with no imputation for missing data.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (week 0) n=147,149,147</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.294" spread="0.210" lower_limit="0.260" upper_limit="0.328"/>
                    <measurement group_id="O2" value="0.314" spread="0.189" lower_limit="0.284" upper_limit="0.345"/>
                    <measurement group_id="O3" value="0.357" spread="0.218" lower_limit="0.321" upper_limit="0.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (week 3) n=133,133,131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.280" spread="0.229" lower_limit="0.241" upper_limit="0.319"/>
                    <measurement group_id="O2" value="0.305" spread="0.211" lower_limit="0.269" upper_limit="0.341"/>
                    <measurement group_id="O3" value="0.334" spread="0.230" lower_limit="0.294" upper_limit="0.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 13) n=117,112,111</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.251" spread="0.223" lower_limit="0.210" upper_limit="0.291"/>
                    <measurement group_id="O2" value="0.316" spread="0.236" lower_limit="0.271" upper_limit="0.360"/>
                    <measurement group_id="O3" value="0.323" spread="0.222" lower_limit="0.281" upper_limit="0.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=108,100,103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.264" spread="0.230" lower_limit="0.220" upper_limit="0.308"/>
                    <measurement group_id="O2" value="0.302" spread="0.239" lower_limit="0.255" upper_limit="0.349"/>
                    <measurement group_id="O3" value="0.343" spread="0.224" lower_limit="0.299" upper_limit="0.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potentially Clinically Significant Heart Rate</title>
        <description>Number of subjects with a heart rate that was lower/higher than a set limit and increased/decreased from set baseline limit in beats per minute (bpm)</description>
        <time_frame>visit 6 (week 27)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Heart Rate</title>
          <description>Number of subjects with a heart rate that was lower/higher than a set limit and increased/decreased from set baseline limit in beats per minute (bpm)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 50 bpm &amp; &gt;= 15 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 120 bpm &amp; &gt;= 25 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Days Used Per Week</title>
        <description>Supplemental medication usage is recorded throughout the study. MDI stands for metered dose inhaler.</description>
        <time_frame>Screening (day-14 to 0) and Treatment (week 0 - 26)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Days Used Per Week</title>
          <description>Supplemental medication usage is recorded throughout the study. MDI stands for metered dose inhaler.</description>
          <population>ITT Population</population>
          <units>Days Used / Week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening Period (day -14 to day 0 pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="2.92" lower_limit="3.62" upper_limit="4.57"/>
                    <measurement group_id="O2" value="3.73" spread="2.95" lower_limit="3.25" upper_limit="4.21"/>
                    <measurement group_id="O3" value="3.84" spread="2.92" lower_limit="3.36" upper_limit="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visits 2-5 (week 0 - 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="2.63" lower_limit="2.33" upper_limit="3.09"/>
                    <measurement group_id="O2" value="2.36" spread="2.60" lower_limit="1.94" upper_limit="2.78"/>
                    <measurement group_id="O3" value="2.52" spread="2.66" lower_limit="2.09" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day</title>
        <description>Supplemental medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.</description>
        <time_frame>Screening (day-14 to 0) and Treatment (week 0 - 26)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Ipratropium Bromide Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day</title>
          <description>Supplemental medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.</description>
          <population>ITT Population</population>
          <units>Actuations / Day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening period (day -14 to day 0 pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="2.72" lower_limit="2.25" upper_limit="3.14"/>
                    <measurement group_id="O2" value="2.43" spread="2.69" lower_limit="1.99" upper_limit="2.86"/>
                    <measurement group_id="O3" value="2.67" spread="3.06" lower_limit="2.18" upper_limit="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visits 2-5 (week 0 - 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="2.28" lower_limit="1.24" upper_limit="1.98"/>
                    <measurement group_id="O2" value="1.59" spread="2.37" lower_limit="1.21" upper_limit="1.97"/>
                    <measurement group_id="O3" value="1.58" spread="2.12" lower_limit="1.24" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Days Used Per Week</title>
        <description>Rescue medication usage during the study. MDI stands for metered dose inhaler.</description>
        <time_frame>Screening (day-14 to 0) and Treatment (week 0 - 26)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Days Used Per Week</title>
          <description>Rescue medication usage during the study. MDI stands for metered dose inhaler.</description>
          <population>ITT Population</population>
          <units>Days Used / Week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening Period (day -14 to day 0 pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="2.85" lower_limit="3.72" upper_limit="4.65"/>
                    <measurement group_id="O2" value="4.20" spread="2.86" lower_limit="3.74" upper_limit="4.66"/>
                    <measurement group_id="O3" value="4.23" spread="2.77" lower_limit="3.78" upper_limit="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visits 2-5 (week 0 - 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="2.64" lower_limit="2.42" upper_limit="3.28"/>
                    <measurement group_id="O2" value="2.44" spread="2.49" lower_limit="2.03" upper_limit="2.84"/>
                    <measurement group_id="O3" value="2.75" spread="2.64" lower_limit="2.32" upper_limit="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day</title>
        <description>Rescue medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.</description>
        <time_frame>Screening (day-14 to 0) and Treatment (week 0 - 26)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Racemic Albuterol or Levalbuterol Metered Dose Inhaler (MDI) Usage: Number of Actuations Per Day</title>
          <description>Rescue medication usage during the study. MDI stands for metered dose inhaler. An actuation is one depression of the device that releases medication.</description>
          <population>ITT Population</population>
          <units>Actuations/Day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening Period (day -14 to day 0 pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="2.80" lower_limit="2.45" upper_limit="3.37"/>
                    <measurement group_id="O2" value="2.68" spread="2.57" lower_limit="2.27" upper_limit="3.10"/>
                    <measurement group_id="O3" value="2.97" spread="3.05" lower_limit="2.47" upper_limit="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visits 2-5 (week 0 - 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="2.27" lower_limit="1.34" upper_limit="2.08"/>
                    <measurement group_id="O2" value="1.56" spread="2.32" lower_limit="1.18" upper_limit="1.93"/>
                    <measurement group_id="O3" value="1.65" spread="2.11" lower_limit="1.31" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-Normalized Area Under the Curve (nAUC) From 0 to 6 Hrs for Forced Expiratory Volume in One Second (FEV1) Changes From Baseline</title>
        <description>Area under the change from baseline curve from 0 to 6 hours. Time-normalized AUC (0-6 hrs) was derived using the linear trapezoidal method.</description>
        <time_frame>weeks 0,3,13,26</time_frame>
        <population>ITT Population. Spirometry measurements collected within 6 hours following in-clinic rescue/supplemental medications use were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Time-Normalized Area Under the Curve (nAUC) From 0 to 6 Hrs for Forced Expiratory Volume in One Second (FEV1) Changes From Baseline</title>
          <description>Area under the change from baseline curve from 0 to 6 hours. Time-normalized AUC (0-6 hrs) was derived using the linear trapezoidal method.</description>
          <population>ITT Population. Spirometry measurements collected within 6 hours following in-clinic rescue/supplemental medications use were excluded from analysis.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (week 0) n=147,149,147</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.191" spread="0.172" lower_limit="0.163" upper_limit="0.219"/>
                    <measurement group_id="O2" value="0.216" spread="0.157" lower_limit="0.191" upper_limit="0.242"/>
                    <measurement group_id="O3" value="0.253" spread="0.179" lower_limit="0.224" upper_limit="0.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (week 3) n=129,129,131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.175" spread="0.204" lower_limit="0.139" upper_limit="0.210"/>
                    <measurement group_id="O2" value="0.208" spread="0.200" lower_limit="0.173" upper_limit="0.243"/>
                    <measurement group_id="O3" value="0.224" spread="0.206" lower_limit="0.188" upper_limit="0.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 13) n=113,110,110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.155" spread="0.210" lower_limit="0.116" upper_limit="0.194"/>
                    <measurement group_id="O2" value="0.214" spread="0.225" lower_limit="0.171" upper_limit="0.256"/>
                    <measurement group_id="O3" value="0.218" spread="0.214" lower_limit="0.177" upper_limit="0.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=107,100,101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161" spread="0.209" lower_limit="0.121" upper_limit="0.201"/>
                    <measurement group_id="O2" value="0.197" spread="0.229" lower_limit="0.152" upper_limit="0.243"/>
                    <measurement group_id="O3" value="0.241" spread="0.209" lower_limit="0.200" upper_limit="0.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transitional (Relative Change in) Dyspnea Index</title>
        <description>The transitional focal score (-9 to 9) is the sum of relative change from baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores (each -3 to 3 scale). A Transitional Dyspnea Index score of -9 represents a maximum degradation of all three tests; a score of 9 represents a maximum improvement of all three tests.</description>
        <time_frame>weeks 13, 26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Transitional (Relative Change in) Dyspnea Index</title>
          <description>The transitional focal score (-9 to 9) is the sum of relative change from baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores (each -3 to 3 scale). A Transitional Dyspnea Index score of -9 represents a maximum degradation of all three tests; a score of 9 represents a maximum improvement of all three tests.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (week 13) n=115,113,114</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="2.40" lower_limit="1.05" upper_limit="1.94"/>
                    <measurement group_id="O2" value="1.47" spread="2.56" lower_limit="0.99" upper_limit="1.95"/>
                    <measurement group_id="O3" value="1.56" spread="2.74" lower_limit="1.05" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=108,102,103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="2.77" lower_limit="0.92" upper_limit="1.97"/>
                    <measurement group_id="O2" value="1.43" spread="2.83" lower_limit="0.88" upper_limit="1.99"/>
                    <measurement group_id="O3" value="1.49" spread="2.76" lower_limit="0.95" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Improved Transitional Dyspnea Index</title>
        <description>The number of participants with a transitional focal score (range -9 to 9) of &gt;=1 improvement. Transitional focal score compares current health against baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.</description>
        <time_frame>weeks 13, 26</time_frame>
        <population>ITT Population. Visit 4 n=115,113,114 Visit 5 n=108,102,103</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Improved Transitional Dyspnea Index</title>
          <description>The number of participants with a transitional focal score (range -9 to 9) of &gt;=1 improvement. Transitional focal score compares current health against baseline for the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.</description>
          <population>ITT Population. Visit 4 n=115,113,114 Visit 5 n=108,102,103</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= 1Unit Improvement, visit 4 (wk13) n=115,113,114</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 1 Unit Improvement,visit 5(wk 26) n=108,102,103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Changes From Baseline for 24 Hour Post Dose Timepoint (Trough)</title>
        <description>The 24 hour trough is the FEV1 value obtained 24 hours post first dose. This value is compared to the baseline FEV1 value.</description>
        <time_frame>weeks 0,3,13,26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Changes From Baseline for 24 Hour Post Dose Timepoint (Trough)</title>
          <description>The 24 hour trough is the FEV1 value obtained 24 hours post first dose. This value is compared to the baseline FEV1 value.</description>
          <population>ITT Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (week 0) n=141,143,141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.162" spread="0.209" lower_limit="0.127" upper_limit="0.197"/>
                    <measurement group_id="O2" value="0.172" spread="0.206" lower_limit="0.138" upper_limit="0.206"/>
                    <measurement group_id="O3" value="0.155" spread="0.226" lower_limit="0.117" upper_limit="0.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (week 3) n=130,130,127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.096" spread="0.192" lower_limit="0.063" upper_limit="0.130"/>
                    <measurement group_id="O2" value="0.124" spread="0.209" lower_limit="0.088" upper_limit="0.161"/>
                    <measurement group_id="O3" value="0.131" spread="0.201" lower_limit="0.096" upper_limit="0.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 13) n=111,108,110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.094" spread="0.192" lower_limit="0.058" upper_limit="0.130"/>
                    <measurement group_id="O2" value="0.116" spread="0.187" lower_limit="0.080" upper_limit="0.152"/>
                    <measurement group_id="O3" value="0.101" spread="0.207" lower_limit="0.062" upper_limit="0.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=105,97,101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.087" spread="0.215" lower_limit="0.046" upper_limit="0.129"/>
                    <measurement group_id="O2" value="0.098" spread="0.243" lower_limit="0.049" upper_limit="0.147"/>
                    <measurement group_id="O3" value="0.137" spread="0.229" lower_limit="0.091" upper_limit="0.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Global Evaluations Change From Baseline</title>
        <description>The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1=much better and 7=much worse. Ratings were assessed relative to the subject's initial entry into the study.</description>
        <time_frame>weeks 13, 26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Subject Global Evaluations Change From Baseline</title>
          <description>The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1=much better and 7=much worse. Ratings were assessed relative to the subject's initial entry into the study.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (week 13) n=112,112,114</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="1.39" lower_limit="-1.23" upper_limit="-0.70"/>
                    <measurement group_id="O2" value="-1.11" spread="1.51" lower_limit="-1.39" upper_limit="-0.82"/>
                    <measurement group_id="O3" value="-0.89" spread="1.49" lower_limit="-1.16" upper_limit="-0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=106,102,102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="1.50" lower_limit="-1.26" upper_limit="-0.68"/>
                    <measurement group_id="O2" value="-1.06" spread="1.41" lower_limit="-1.33" upper_limit="-0.78"/>
                    <measurement group_id="O3" value="-0.83" spread="1.70" lower_limit="-1.17" upper_limit="-0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Global Evaluations Change From Baseline</title>
        <description>The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse. Ratings were assessed relative to the subject's initial entry into the study.</description>
        <time_frame>weeks 13, 26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Evaluations Change From Baseline</title>
          <description>The global evaluation is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse. Ratings were assessed relative to the subject's initial entry into the study.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (week 13) n=111,112,110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="1.27" lower_limit="-0.90" upper_limit="-0.42"/>
                    <measurement group_id="O2" value="-0.88" spread="1.27" lower_limit="-1.11" upper_limit="-0.64"/>
                    <measurement group_id="O3" value="-0.75" spread="1.43" lower_limit="-1.02" upper_limit="-0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=106,100,100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="1.20" lower_limit="-0.97" upper_limit="-0.51"/>
                    <measurement group_id="O2" value="-0.74" spread="1.28" lower_limit="-0.99" upper_limit="-0.49"/>
                    <measurement group_id="O3" value="-0.76" spread="1.65" lower_limit="-1.09" upper_limit="-0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BODE Index</title>
        <description>The BODE index (0=relative health and 10=severe chronic obstructive pulmonary disease) is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the 6-minute walk test. Scores were derived using pre-dose assessments from each visit.</description>
        <time_frame>Baseline (visit 2), weeks 13, 26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>BODE Index</title>
          <description>The BODE index (0=relative health and 10=severe chronic obstructive pulmonary disease) is a multi-dimension COPD grading system that incorporates body-mass index (B), degree of airflow obstruction (O), dyspnea (D), and exercise capacity (E) as measured by the 6-minute walk test. Scores were derived using pre-dose assessments from each visit.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (baseline- week 0) n=146,148,147</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" spread="1.58"/>
                    <measurement group_id="O2" value="4.98" spread="1.64"/>
                    <measurement group_id="O3" value="5.14" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 13) n=110,108,109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" spread="2.03"/>
                    <measurement group_id="O2" value="3.97" spread="1.90"/>
                    <measurement group_id="O3" value="4.28" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=103,100,101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" spread="1.91"/>
                    <measurement group_id="O2" value="3.94" spread="1.99"/>
                    <measurement group_id="O3" value="4.11" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6-Minute Walk: Change From Baseline in the Distance Walked in 6 Minutes</title>
        <description>Mean change from baseline in distance walked (meters)</description>
        <time_frame>Post-Dose weeks 0, 13, 26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>6-Minute Walk: Change From Baseline in the Distance Walked in 6 Minutes</title>
          <description>Mean change from baseline in distance walked (meters)</description>
          <population>ITT Population</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (week 0 - post dose) n=146,148,146</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.28" spread="81.22" lower_limit="2.00" upper_limit="28.56"/>
                    <measurement group_id="O2" value="15.72" spread="67.59" lower_limit="4.74" upper_limit="26.70"/>
                    <measurement group_id="O3" value="12.37" spread="69.65" lower_limit="0.97" upper_limit="23.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 13 - post dose) n=116,110,112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.05" spread="104.90" lower_limit="-3.24" upper_limit="35.34"/>
                    <measurement group_id="O2" value="4.13" spread="128.01" lower_limit="-20.06" upper_limit="28.32"/>
                    <measurement group_id="O3" value="31.07" spread="77.20" lower_limit="16.61" upper_limit="45.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26 - post dose) n=106,97,103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.42" spread="94.19" lower_limit="6.28" upper_limit="42.56"/>
                    <measurement group_id="O2" value="1.24" spread="135.05" lower_limit="-25.98" upper_limit="28.46"/>
                    <measurement group_id="O3" value="37.00" spread="85.01" lower_limit="20.38" upper_limit="53.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in St. George's Respiratory Questionnaire</title>
        <description>Scores are expressed as a mean change from baseline of overall impairment (total score). The questionnaire has a scale of 100 which represents worst possible health status to 0 which indicates best possible health status.</description>
        <time_frame>weeks 13, 26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in St. George's Respiratory Questionnaire</title>
          <description>Scores are expressed as a mean change from baseline of overall impairment (total score). The questionnaire has a scale of 100 which represents worst possible health status to 0 which indicates best possible health status.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (week 13) n=105,102,105</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.16" spread="10.09" lower_limit="-6.11" upper_limit="-2.21"/>
                    <measurement group_id="O2" value="-3.44" spread="12.10" lower_limit="-5.81" upper_limit="-1.06"/>
                    <measurement group_id="O3" value="-1.92" spread="9.86" lower_limit="-3.82" upper_limit="-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=97,94,97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.76" spread="10.06" lower_limit="-8.78" upper_limit="-4.73"/>
                    <measurement group_id="O2" value="-3.73" spread="13.14" lower_limit="-6.42" upper_limit="-1.04"/>
                    <measurement group_id="O3" value="-3.68" spread="11.78" lower_limit="-6.06" upper_limit="-1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a &gt;=4 Unit Improvement on the St. George's Respiratory Questionnaire</title>
        <description>Scores are expressed as the number of participants with &gt;= 4 unit improvement in overall impairment (total score), where 100 represents worst possible health status and 0 indicates best possible health status.</description>
        <time_frame>Visit 4 (week 13) , Visit 5 (week 26)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a &gt;=4 Unit Improvement on the St. George's Respiratory Questionnaire</title>
          <description>Scores are expressed as the number of participants with &gt;= 4 unit improvement in overall impairment (total score), where 100 represents worst possible health status and 0 indicates best possible health status.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (week 13) n=105,102,105</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=97,94,97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Medical Research Council Dyspnea Questionaire</title>
        <description>Scores range from 0 to 4, with a score of 4 indicating that a subject is too breathless to leave the house or becomes breathless when dressing or undressing. The highest numbered question to which the subject answered 'Yes' is the Dyspnea Scale Score.</description>
        <time_frame>Baseline (visit 2), weeks 13, 26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Modified Medical Research Council Dyspnea Questionaire</title>
          <description>Scores range from 0 to 4, with a score of 4 indicating that a subject is too breathless to leave the house or becomes breathless when dressing or undressing. The highest numbered question to which the subject answered 'Yes' is the Dyspnea Scale Score.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (visit 2, week 0) n=147,149,145</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="0.78"/>
                    <measurement group_id="O2" value="2.76" spread="0.79"/>
                    <measurement group_id="O3" value="2.91" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (week 3) n=132,131,128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="1.02"/>
                    <measurement group_id="O2" value="2.47" spread="0.96"/>
                    <measurement group_id="O3" value="2.50" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 13) n=117,113,115</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="1.03"/>
                    <measurement group_id="O2" value="2.10" spread="1.05"/>
                    <measurement group_id="O3" value="2.43" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=107,103,103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" spread="1.10"/>
                    <measurement group_id="O2" value="2.09" spread="1.14"/>
                    <measurement group_id="O3" value="2.26" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent (%) of Participants With an Improved Transitional Dyspnea Index</title>
        <description>The percentage of participants with a transitional focal score (range -9 to 9) of &gt;=1 improvement. Transitional focal score is the sum of the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.</description>
        <time_frame>visits 4 (week 13), visit 5 (week 26)</time_frame>
        <population>ITT population. Percentages were based on the number of subjects with non-missing data.
Visit 4 n=115, 113, 114 Visit 5 n=108, 102, 103</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Percent (%) of Participants With an Improved Transitional Dyspnea Index</title>
          <description>The percentage of participants with a transitional focal score (range -9 to 9) of &gt;=1 improvement. Transitional focal score is the sum of the Functional Impairment, Magnitude of Task, and Magnitude of Effort scores. A score of -9 is maximum worsening and 9 is maximum improvement.</description>
          <population>ITT population. Percentages were based on the number of subjects with non-missing data.
Visit 4 n=115, 113, 114 Visit 5 n=108, 102, 103</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=1 Unit Improvement,visit 4 (wk 13) n=115,113,114</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3"/>
                    <measurement group_id="O2" value="52.2"/>
                    <measurement group_id="O3" value="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 Unit Improvement,visit 5 (wk 26) n=108,102,103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="48.0"/>
                    <measurement group_id="O3" value="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent (%) of Participants With a &gt;=4 Unit Improvement in the St. George's Respiratory Questionaire</title>
        <description>Percent of participants with a &gt;=4 unit improvement in the overall impairment (total score) of the St. George's Respiratory Questionaire. This questionaire uses a 100 - 0 scale, where 100 represents the worst possible health status and 0 indicates the best possible health status.</description>
        <time_frame>visit 4 (week 13), visit 5 (week 26)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Percent (%) of Participants With a &gt;=4 Unit Improvement in the St. George's Respiratory Questionaire</title>
          <description>Percent of participants with a &gt;=4 unit improvement in the overall impairment (total score) of the St. George's Respiratory Questionaire. This questionaire uses a 100 - 0 scale, where 100 represents the worst possible health status and 0 indicates the best possible health status.</description>
          <population>ITT population</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4 (week 13), n=105,102,105</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="46.1"/>
                    <measurement group_id="O3" value="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26), n=97,94,97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7"/>
                    <measurement group_id="O2" value="45.7"/>
                    <measurement group_id="O3" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for the 6-Minute Walk Test: Distance Walked in Meters</title>
        <description>This test measures the participants' level of fitness. It is a measure of the distance the participant can walk in 6 minutes.</description>
        <time_frame>Baseline (Visit 2), week 13, week 26</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Values for the 6-Minute Walk Test: Distance Walked in Meters</title>
          <description>This test measures the participants' level of fitness. It is a measure of the distance the participant can walk in 6 minutes.</description>
          <population>ITT population</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (week 0) Pre-Dose n=147, 148, 147</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.84" spread="155.43"/>
                    <measurement group_id="O2" value="315.94" spread="131.74"/>
                    <measurement group_id="O3" value="328.36" spread="183.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (week 0) Post-Dose n=146, 149, 146</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.19" spread="163.27"/>
                    <measurement group_id="O2" value="332.80" spread="135.79"/>
                    <measurement group_id="O3" value="339.81" spread="194.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 13) Pre-Dose n=115, 111, 111</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344.95" spread="175.53"/>
                    <measurement group_id="O2" value="332.25" spread="140.60"/>
                    <measurement group_id="O3" value="333.63" spread="150.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 13) Post-Dose n=116, 111, 112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.51" spread="167.90"/>
                    <measurement group_id="O2" value="337.28" spread="165.02"/>
                    <measurement group_id="O3" value="337.68" spread="155.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) Pre-Dose n=105, 100, 103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355.83" spread="181.84"/>
                    <measurement group_id="O2" value="338.21" spread="129.68"/>
                    <measurement group_id="O3" value="337.25" spread="167.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) Post-Dose n=106, 98, 103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.72" spread="169.96"/>
                    <measurement group_id="O2" value="344.98" spread="122.38"/>
                    <measurement group_id="O3" value="348.11" spread="174.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for Investigator Global Evaluations</title>
        <description>The investigator global evaluation is reported by the study investigator. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.</description>
        <time_frame>Baseline (Visit 2), Weeks 13, 26</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Values for Investigator Global Evaluations</title>
          <description>The investigator global evaluation is reported by the study investigator. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Baseline, Week 0) n=145,148,144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="0.88"/>
                    <measurement group_id="O2" value="3.88" spread="0.77"/>
                    <measurement group_id="O3" value="3.84" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 13) n=113,112,112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="1.05"/>
                    <measurement group_id="O2" value="3.04" spread="1.17"/>
                    <measurement group_id="O3" value="3.04" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=107,100,102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" spread="1.04"/>
                    <measurement group_id="O2" value="3.16" spread="1.28"/>
                    <measurement group_id="O3" value="3.01" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for St. George's Respiratory Questionnaire</title>
        <description>A questionnaire to assess respiratory health. Scores are expressed as a percentage of overall impairment (total score), where 100 represents the worst possible health status and 0 indicates best possible health status.</description>
        <time_frame>Baseline (Visit 2), weeks 13, 26</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Values for St. George's Respiratory Questionnaire</title>
          <description>A questionnaire to assess respiratory health. Scores are expressed as a percentage of overall impairment (total score), where 100 represents the worst possible health status and 0 indicates best possible health status.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (Baseline; week 0) n=136,141,144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.86" spread="14.90"/>
                    <measurement group_id="O2" value="49.36" spread="17.38"/>
                    <measurement group_id="O3" value="52.40" spread="17.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 13) n=114, 105, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.48" spread="16.53"/>
                    <measurement group_id="O2" value="43.64" spread="18.94"/>
                    <measurement group_id="O3" value="49.95" spread="19.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=105, 97, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.72" spread="16.35"/>
                    <measurement group_id="O2" value="42.69" spread="17.98"/>
                    <measurement group_id="O3" value="48.09" spread="20.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for Subject Global Evaluations</title>
        <description>The subject global evaluation is reported by study subjects/participants. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.</description>
        <time_frame>Baseline (Visit 2), weeks 13, 26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Values for Subject Global Evaluations</title>
          <description>The subject global evaluation is reported by study subjects/participants. It is a COPD symptoms rating ranging from 1 to 7, with 1 = much better and 7 = much worse.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (baseline; week 0) n=145, 148, 146</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="1.08"/>
                    <measurement group_id="O2" value="3.97" spread="1.08"/>
                    <measurement group_id="O3" value="3.86" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (week 13) n=114, 113, 115</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="1.09"/>
                    <measurement group_id="O2" value="2.88" spread="1.26"/>
                    <measurement group_id="O3" value="2.94" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (week 26) n=108, 103, 103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="1.31"/>
                    <measurement group_id="O2" value="2.96" spread="1.32"/>
                    <measurement group_id="O3" value="2.94" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for Inspiratory Capacity</title>
        <description>Inspiratory capacity is the maximum volume that can be inhaled.</description>
        <time_frame>Baseline (Visit 2), Weeks 3, 13, 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Values for Inspiratory Capacity</title>
          <description>Inspiratory capacity is the maximum volume that can be inhaled.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (wk 0, baseline) pre-dose; n=80,86,82</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.739" spread="0.630"/>
                    <measurement group_id="O2" value="1.864" spread="0.551"/>
                    <measurement group_id="O3" value="1.764" spread="0.577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (wk 3) pre-dose; n=81,83,74</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.826" spread="0.654"/>
                    <measurement group_id="O2" value="1.889" spread="0.558"/>
                    <measurement group_id="O3" value="1.909" spread="0.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (wk 13) pre-dose; n=100,94,99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.874" spread="0.676"/>
                    <measurement group_id="O2" value="1.890" spread="0.656"/>
                    <measurement group_id="O3" value="1.962" spread="0.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (wk 26) pre-dose; n=106,101,101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.817" spread="0.620"/>
                    <measurement group_id="O2" value="1.901" spread="0.630"/>
                    <measurement group_id="O3" value="2.070" spread="0.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (wk 0, baseline) post dose; n=80,85,81</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.976" spread="0.730"/>
                    <measurement group_id="O2" value="2.161" spread="0.624"/>
                    <measurement group_id="O3" value="2.109" spread="0.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VIsit 3 (wk 3) post dose; n=82,81,74</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.973" spread="0.685"/>
                    <measurement group_id="O2" value="2.111" spread="0.627"/>
                    <measurement group_id="O3" value="2.108" spread="0.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (wk 13) post dose; n=98,94,99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.089" spread="0.729"/>
                    <measurement group_id="O2" value="2.081" spread="0.658"/>
                    <measurement group_id="O3" value="2.176" spread="0.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (wk 26) post dose; n=105,100,101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.978" spread="0.690"/>
                    <measurement group_id="O2" value="2.084" spread="0.613"/>
                    <measurement group_id="O3" value="2.273" spread="0.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Values for Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Forced Expiratory Volume in one second</description>
        <time_frame>Baseline (Visit 2), weeks 3, 13, 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Formoterol 12 Mcg 2x/Day</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 15 Mcg 2x/Day</title>
          </group>
          <group group_id="O3">
            <title>Arformoterol 25 Mcg 2x/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Values for Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Forced Expiratory Volume in one second</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 2 (wk 0, baseline) pre dose; n=147,149,147</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.210" spread="0.420"/>
                    <measurement group_id="O2" value="1.222" spread="0.465"/>
                    <measurement group_id="O3" value="1.204" spread="0.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (wk 0) 24 hr; n=141,143,141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.378" spread="0.497"/>
                    <measurement group_id="O2" value="1.400" spread="0.545"/>
                    <measurement group_id="O3" value="1.360" spread="0.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (wk 3) pre dose; n=129,129,132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.311" spread="0.458"/>
                    <measurement group_id="O2" value="1.323" spread="0.484"/>
                    <measurement group_id="O3" value="1.327" spread="0.477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (wk 3) 24 hr; n=130,130,127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.310" spread="0.456"/>
                    <measurement group_id="O2" value="1.346" spread="0.490"/>
                    <measurement group_id="O3" value="1.355" spread="0.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (wk 13) pre dose; n=113,111,111</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.281" spread="0.470"/>
                    <measurement group_id="O2" value="1.310" spread="0.483"/>
                    <measurement group_id="O3" value="1.308" spread="0.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (wk 13) 24 hr; n=111,108,110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.316" spread="0.461"/>
                    <measurement group_id="O2" value="1.331" spread="0.460"/>
                    <measurement group_id="O3" value="1.294" spread="0.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (wk 26) pre dose; n=107,102,101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.283" spread="0.466"/>
                    <measurement group_id="O2" value="1.291" spread="0.453"/>
                    <measurement group_id="O3" value="1.325" spread="0.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (wk 26) 24 hr; n=105,97,101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.296" spread="0.455"/>
                    <measurement group_id="O2" value="1.314" spread="0.467"/>
                    <measurement group_id="O3" value="1.360" spread="0.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (wk 0) 6 hr; n=142,145,138</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.383" spread="0.511"/>
                    <measurement group_id="O2" value="1.410" spread="0.533"/>
                    <measurement group_id="O3" value="1.428" spread="0.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (wk 3) 6 hr; n=130,125,127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.338" spread="0.464"/>
                    <measurement group_id="O2" value="1.386" spread="0.504"/>
                    <measurement group_id="O3" value="1.386" spread="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (wk 13) 6 hr; n=109,109,104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.339" spread="0.487"/>
                    <measurement group_id="O2" value="1.385" spread="0.482"/>
                    <measurement group_id="O3" value="1.361" spread="0.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visti 5 (wk 26) 6 hr; n=101,95,101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.310" spread="0.475"/>
                    <measurement group_id="O2" value="1.355" spread="0.457"/>
                    <measurement group_id="O3" value="1.384" spread="0.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Formoterol 12 Mcg 2x/Day</title>
        </group>
        <group group_id="E2">
          <title>Arformoterol 15 Mcg 2x/Day</title>
        </group>
        <group group_id="E3">
          <title>Arformoterol 25 Mcg 2x/Day</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14"/>
                <counts group_id="E2" subjects_affected="20"/>
                <counts group_id="E3" subjects_affected="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Gasteroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Stent occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung carcinoma, cell type unspecified, Stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Diaphragmatic paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96"/>
                <counts group_id="E2" subjects_affected="97"/>
                <counts group_id="E3" subjects_affected="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Oral Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="147"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E3" events="21" subjects_affected="15" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="147"/>
                <counts group_id="E2" events="45" subjects_affected="34" subjects_at_risk="149"/>
                <counts group_id="E3" events="43" subjects_affected="35" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In addition to the &lt;60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Please see dropout rate in participant group. Sunovion is unaware of any other limitations or caveats associated with this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sepracor Inc.</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

